Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

This study tests the combination of glofitamab (an immune therapy that directs T-cells to attack lymphoma cells) with chidamide (an oral drug that makes cancer cells more vulnerable) in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) — meaning the cancer came back or never fully responded to initial treatment. **You may be eligible if:** - You are 18 or older with confirmed DLBCL (including high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma, or follicular lymphoma that transformed to DLBCL) - Your lymphoma came back or did not respond to at least one prior treatment - You are willing to comply with hospitalization requirements following glofitamab doses - You have a pathology report from initial diagnosis available **You may NOT be eligible if:** - You have never been treated for DLBCL before (this study is for relapsed/refractory patients) - You have active or uncontrolled infection - You have other significant health conditions preventing study participation - Your general health is too poor to tolerate the treatment regimen Talk to your doctor to see if this trial is right for you.